Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ELDNNASDAQ:LBPHNYSE:OGENNASDAQ:SPRB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELDNEledon Pharmaceuticals$2.02+2.5%$1.80$1.07▼$2.95$48.88M0.87120,234 shs67,377 shsLBPHLongboard Pharmaceuticals$19.25-2.5%$20.08$3.60▼$28.15$711.34M1.24374,063 shs278,620 shsOGENOragenics$1.06-2.8%$1.78$1.02▼$7.74$4.75M0.3156,083 shs59,496 shsSPRBSpruce Biosciences$0.70$2.44$0.67▼$5.95$28.88M2.52727,620 shs377,244 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELDNEledon Pharmaceuticals+2.54%+1.51%-4.72%+10.99%-9.82%LBPHLongboard Pharmaceuticals-2.53%+6.89%-4.28%-17.28%+152.96%OGENOragenics-3.64%-7.83%-23.74%-82.73%-62.14%SPRBSpruce Biosciences-0.11%0.00%+0.14%-79.38%-66.30%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELDNEledon Pharmaceuticals3.7359 of 5 stars3.55.00.00.03.91.71.3LBPHLongboard Pharmaceuticals0.9315 of 5 stars3.52.00.00.00.01.70.0OGENOragenicsN/AN/AN/AN/AN/AN/AN/AN/ASPRBSpruce Biosciences3.4784 of 5 stars4.15.00.00.00.02.51.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELDNEledon Pharmaceuticals3.00Buy$10.67428.05% UpsideLBPHLongboard Pharmaceuticals3.00Buy$44.80132.73% UpsideOGENOragenicsN/AN/AN/AN/ASPRBSpruce Biosciences2.25Hold$5.67708.37% UpsideCurrent Analyst RatingsLatest ELDN, LBPH, OGEN, and SPRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.004/10/2024LBPHLongboard PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$60.003/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/15/2024LBPHLongboard PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.003/14/2024SPRBSpruce BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$8.00 ➝ $3.003/14/2024SPRBSpruce BiosciencesLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/14/2024SPRBSpruce BiosciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/14/2024SPRBSpruce BiosciencesSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $2.003/14/2024SPRBSpruce BiosciencesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Sector Perform$9.00 ➝ $2.003/14/2024SPRBSpruce BiosciencesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral3/14/2024SPRBSpruce BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELDNEledon PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ALBPHLongboard PharmaceuticalsN/AN/AN/AN/A$1.67 per shareN/AOGENOragenics$40K118.75N/AN/A$0.61 per share1.74SPRBSpruce Biosciences$10.09M2.86N/AN/A$1.88 per share0.37Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELDNEledon Pharmaceuticals-$40.33M-$1.79N/AN/AN/AN/A-46.15%-43.10%5/9/2024 (Estimated)LBPHLongboard Pharmaceuticals-$54.42M-$2.38N/AN/AN/AN/A-97.53%-85.21%5/14/2024 (Estimated)OGENOragenics-$20.66M-$9.25N/A∞N/AN/A-397.35%-246.95%N/ASPRBSpruce Biosciences-$47.92M-$1.25N/AN/AN/A-474.96%-52.31%-39.77%5/20/2024 (Estimated)Latest ELDN, LBPH, OGEN, and SPRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023OGENOragenicsN/A-$5.48-$5.48-$5.48N/AN/A3/28/2024Q4 2023ELDNEledon Pharmaceuticals-$0.38-$0.29+$0.09-$0.29N/AN/A3/13/2024Q4 2023SPRBSpruce Biosciences-$0.41-$0.23+$0.18-$0.23$1.65 million$2.89 million3/12/2024Q4 2023LBPHLongboard Pharmaceuticals-$0.60-$0.62-$0.02-$0.62N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELDNEledon PharmaceuticalsN/AN/AN/AN/AN/ALBPHLongboard PharmaceuticalsN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELDNEledon PharmaceuticalsN/A14.4114.41LBPHLongboard PharmaceuticalsN/A5.145.14OGENOragenicsN/A2.152.15SPRBSpruce Biosciences0.024.184.18OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELDNEledon Pharmaceuticals56.77%LBPHLongboard Pharmaceuticals63.28%OGENOragenics18.71%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipELDNEledon Pharmaceuticals19.40%LBPHLongboard Pharmaceuticals4.64%OGENOragenics24.60%SPRBSpruce Biosciences9.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableELDNEledon Pharmaceuticals1724.81 million20.00 millionOptionableLBPHLongboard Pharmaceuticals5036.02 million34.35 millionOptionableOGENOragenics54.48 million3.38 millionN/ASPRBSpruce Biosciences2941.15 million37.41 millionOptionableELDN, LBPH, OGEN, and SPRB HeadlinesSourceHeadlineSpruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meetingbusinesswire.com - April 22 at 4:05 PMSpruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Analystsamericanbankingnews.com - April 20 at 4:34 AMIMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 19 at 4:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 5 at 7:00 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBprnewswire.com - April 4 at 7:15 PMONGOING SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 4 at 7:00 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 3 at 3:30 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - April 1 at 6:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 30 at 6:20 PMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 29 at 5:00 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 28 at 3:30 AMSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce Biosciences, Inc. - SPRBprnewswire.com - March 27 at 5:36 PMSpruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Knowzacks.com - March 27 at 1:01 PMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 27 at 3:30 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 26 at 3:30 AMONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 25 at 4:30 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 24 at 7:00 AMRevenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)finance.yahoo.com - March 23 at 10:38 AMINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 23 at 7:00 AMINVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 22 at 7:00 AMHoldings A/S Novo Sells 359,979 Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB) Stockinsidertrades.com - March 22 at 6:24 AMSpruce Biosciences (SPRB) Falls 86% in a Month: Here's Whyzacks.com - March 21 at 11:21 AMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 21 at 3:30 AMIMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Spruce Biosciences, Inc. and Encourages Investors with Losses to Contact the Firmaccesswire.com - March 20 at 7:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsEledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Longboard PharmaceuticalsNASDAQ:LBPHLongboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.OragenicsNYSE:OGENOragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Spruce BiosciencesNASDAQ:SPRBSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.